This page shows the latest Hal Barron news and features for those working in and with pharma, biotech and healthcare.
Results are expected in 2021. “We believe this drug has the potential to transform the treatment landscape for patients with [these infections] who currently have limited therapeutic options,” commented Hal Barron
Hal Barron, chief scientific officer, GSK. GSK said the study would be the basis for regulatory filings for the ADC later this year, and chief scientific officer Hal Barron said he
Elsewhere, daprodustat is in phase 3 testing. Hal Barron, chief scientific officer, GSK. ... GSK chief scientific officer Hal Barron said there are around 3.5 million people in Japan with anaemia related to CKD, which “can result in weakness and
On the surface, his replacement is a good fit for the new direction GSK is taking under the leadership of CEO Emma Walmsley and CSO Hal Barron. ... At GSK, Martinez-Davis will oversee US pharmaceuticals across all diseases but, if pipeline programmes
'Consensus-led' research being replaced with bold decision-making. GlaxoSmithKline’s research and development leader Dr Hal Barron says he has swept away a longstanding consensus-led and risk-averse approach ... Hal Barron. “We’re all human, so if
Since then, GSK has appointed heavy hitter Hal Barron as its R&D chief, fleshed out its pipeline with the acquisition of Tesaro, renewed a push into oncology, and cut 30%
More from news
Approximately 1 fully matching, plus 46 partially matching documents found.
Walmsley has impressed with a few high-profile hirings to key positions, including Dr Hal Barron as its new R&D supremo, but it will take a few years to see
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
years. Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. ... Sin will report to Hal Barron and will be based at the group’s San Francisco office.
He has served as CEO at Calico, Google's health research business, since its formation in September 2013 and has since been joined by former Genentech/Roche colleagues Hal Barron, David
Hal Barron among four new appointments. Dr Hal Barron has left his role as chief medical officer of Swiss pharma company Roche to join Google's recently-launched health research arm ... Dr Barron is one of four new recruits from industry and academia to
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...